Today, Google unveiled a range of software updates for Android Auto and vehicles equipped with Google integration. At the forefront, Google says its drivers will now be able to join WebEx or Zoom meetings, a feature it previously announced at I/O 2023. The apps will only work in an audio-only capability, which Google says will make it “easy and safe” for drivers to quickly join scheduled meetings from car displays.

Beyond enhancing productivity, Google is also attempting to expand its audio and visual entertainment offerings with its rollout of Prime Video on the Google Play app. This feature, which will appear on the display for “parked entertainment,” will only be available for select vehicles — namely Renault, Polestar and Volvo Cars. Eventually, Google says this will appear in other brands. In addition to streaming, Chrome-based internet browsing will be available starting today. Internet browsing is already available in some cars on Google Play through the standalone app, Vivaldi.

Google

While keeping drivers productive and entertained, Google is also expanding the functionality of the display by making the Weather Channel app available for hourly forecasts, and a follow-me alert safety feature that allows third parties to track your vehicle. A “Trip View” radar will also display live maps — mainly for severe weather events.

Lastly, Google’s digital car key — which allows drivers to use their phones to lock and unlock their vehicles — will finally be available in select Hyundai, Genesis, and Kia models in the US and Canada for those with compatible Pixel and Samsung devices. The tech will also allow drivers to share digital keys with family and friends wirelessly. Digital keys will have already been available in several European countries.

An FDA medical advisory panel ruled that phenylephrine (PE), a key ingredient in many over-the-counter cold medications, does not actually work to treat nasal congestion when taken orally at the recommended 10 mg dose every 4 hours. Phenylephrine was last evaluated for over-the-counter use as an oral and intranasal decongestant in 1976, according to the panel. If you're keeping score at home, that means many of the OTC decongestants consumers in the US have been buying for nearly the last 50 years were, according to the FDA, "failed to provide any benefit over [a] placebo."

This determination will impact drug makers that use PE as an active ingredient, which can be found in Sudafed, Vicks Sinex, and Benadryl Allergy Plus Congestion, for example.

As part of the panel’s review, the FDA reported that in 2022, an estimated 242 million packages of OTC cough and allergy oral products containing PE were sold in retail stores, which raked in about $1.8 billion in sales. It even notes that the true extent of use of PE-containing cold products is likely underestimated because retail sales data does not “capture sales activity from Costco, convenience stores, specialty stores, internet sales, phone sales, or kiosks.”

The FDA will now need to determine if it will revoke PE’s oral OTC designation as “safe and effective.” Without that designation, drug makers may see their products removed from stores.

According to Semafor, data from NewsWhip showed that engagement on public posts linked to the New York Times website has dropped dramatically since late July. This is seemingly a unique issue to the NYT as other news organizations like CNN, the Washington Post, and the BBC have not seen similar dips in engagement.

According to the report, the New York Times' reach hasn't changed on Facebook and other social media platforms. Additionally, recent tweets by former President Barack Obama that include NYT links saw less engagement when compared to his other tweets. For example, when Obama shared articles about healthcare costs, his posts reached fewer than 800,000 users. Most of his posts reach a minimum of 10 million users.

While it's unclear what exactly is causing the drop in user reach, this wouldn't be the first time Elon Musk's X appeared to be affecting user engagement. In August, X was reported to be interfering with links to Mastodon, Bluesky, Threads, Substack and of course—the New York Times, to make them load noticeably slower. At the time, it appeared that the high-profile websites affected were only big names that Musk publicly attacked in the past.

X and The New York Times could not be immediately reached for comment.

As part of Samsung's fall sale event, you can get a Samsung Galaxy Watch 6 for as little as $100 with a new phone purchase. The phones eligible for this bundle deal include the Samsung Galaxy S23 Ultra and the Samsung Galaxy Z Fold 5.

The Watch 6, which debuted in August at a starting price of $300, is effectively getting a $200 price drop in this deal. That might be compelling if you already need a new phone and are on the fence about a smartwatch.

The exact savings you can get with a purchase will vary depending on the size of the watch and if you choose a Bluetooth or LTE model. The basic 40mm size with Bluetooth connectivity will run $100 as part of the bundle, while upgrading to 44mm will cost $110, down from $330. On the LTE side of things, the 40mm and 44mm varieties go for $120 and $130, respectively. That top-spec version technically shaves $250 off the retail price, so spend a little more, save a little more.

For those that don’t need a watch, you can alternatively get the Galaxy Buds 2 Pro for $130 off with your purchase. The Buds 2 Pro, which comes in white, purple, or graphite, normally sells for $230 but can now be purchased for $50 with a phone. However, if both a smartwatch and a new pair of wireless earbuds don't tickle your fancy, you can add a Galaxy Tab S9 to your Android collection instead. You can save up to $230 on the 256 GB beige tablet. It originally goes for $920, but with this deal will only cost $690, but only if you get the Galaxy S 23 Ultra.

Follow @EngadgetDeals on Twitter and subscribe to the Engadget Deals newsletter for the latest tech deals and buying advice.

Clogs in water recovery systems on the international space station have been so backed up that hoses have had to be sent back to Earth for cleaning and refurbishing. This is thanks to the build up of biofilms: a consortium of microorganisms that stick to each other, and often also to surfaces — the insides of water recover tubing, for instance. These microbial or fungal growths can clog filters in water processing systems and make astronauts sick.

So space, like Earth, has a germ problem – so what? Because biofilms can compromise the integrity of and damage equipment, including space suits, recycling units, radiators and water treatment facilities, it can cost space agencies loads of money to replace affected materials. For the full year of 2023, NASA has dedicated a whopping $1.3 billion as part of its budget to resupply its cargo missions to the ISS. Preventing microbial growth in encapsulated space missions will be especially critical for long-haul journeys to places like the moon or Mars, where a quick return to Earth for repairs or treatment of sick astronauts is less feasible.

In a cross collaboration between researchers at the University of Colorado, MIT and the NASA Ames Research Center, researchers studied samples from the space station using a specific and well-understood gram-negative kind of bacteria. The scientists also joined forces with experts at LiquiGlide, a company run by MIT researcher Kripa Varanasi that specializes in “eliminating the friction between solids and liquids.” The multidisciplinary study found covering surfaces with a thin layer of nucleic acids prevented bacterial growth on the ISS-exposed samples. 

Space Biofilm Program

The scientists concluded that these acids carried a slight negative electric charge that stopped microbes from sticking to surfaces. It's worth noting though, that the bacteria were up against a unique physical barrier as well as a chemical one: testing surfaces were etched into "nanograss." These silicon spikes, which resembled a tiny forest, were then slicked with a silicon oil, creating a slippery surface which biofilms struggled to adhere to.

Applying this specific method of covering surfaces with nucleic acids to prevent biofilm buildup showed that in the terrestrial samples, microbial formation was reduced by about 74 percent. Surprisingly the space station samples showed an even more drastic reduction of about 86 percent. However, one recommendation the team has made, based on these initial results, is that longer-duration tests should be carried out on a future mission. Pamela Flores, a microbiology expert at the University of Colorado who participated in the study said that, “We don’t know for how long it will be able to keep up this performance,” in a statement. “So we definitely recommend a longer time of incubation, and also, if possible, a continuous analysis, and not just end points.”

Researchers at Brigham and Women’s Hospital in Boston have developed an implant, notably as small as a grain of rice, that can test the effects of drugs on a patient’s brain tumor in real-time during surgery. Currently, monitoring the effects of drugs on a brain cancer patient during surgery is limited to intraoperative brain imaging and tissue sampling after a drug has been administered. The technique known as microdialysis currently stands as one of the more minimally invasive sampling options for testing the impact of drugs on brain tumors, but even that requires an entire catheter to be inserted into the patient’s skull cavity.

During development, researchers from Brigham and Women’s Hospital designed the device specifically to help test treatments in patients with brain cancers or gliomas, a type of tumor that originates in the brain or spinal cord. The device is designed to only remain implanted in a patient for about two to three hours while it delivers microdoses of the respective drug that is under observation. It can observe the impact of up to 20 drugs on the market for cancerous tumors, according to the researchers. Once the device is removed (sometime before the surgery ends), the surrounding tissue is returned to the lab for analysis.

In a statement published Wednesday, Pierpaolo Peruzzi, co-principal investigator and assistant professor in the Department of Neurosurgery at Brigham and Women’s Hospital said that knowing the impact of cancer drugs on these tumors is critical. “We need to be able to understand, early on, which drug works best for any given patient,” he said.

Brigham and Women’s Hospital

During the development process, researchers at the Brigham and Women’s Hospital ran a clinical trial to observe the actual impact of the implant on real patients. The study found that none of the patients in the trial experienced any adverse effects. The researchers were able to collect biological data from the devices, such as what molecular changes happened when each drug was administered. While the study demonstrated that the implant could be easily incorporated into surgical practice, the researchers are still determining how the data it can gather should be used to optimize tumor therapy.

The researchers are now conducting another study that focuses on implanting the device through a minimally invasive procedure 72 hours before their main surgery. Advancements in the cancer treatment space continue to expand, with new iterations of drug cocktails and viruses that can fight cancer cells emerging in the biotech space. Implants like the one developed by the Brigham and Women’s Hospital bring scientists one step closer to better being able to use tools and data to provide more personalized care treatment plans for cancer patients.

Researchers at Northwestern University developed a bioelectric implant that can detect temperature fluctuations that typically happen right before a body rejects an organ transplant. The sensor is smaller than a fingernail, and a mere 220 micrometers thick.

This new sensor technology is thin enough to sit directly on a kidney's fibrous layer — called the renal capsule — which surrounds and protects the organ. The device works by continuously monitoring changes to blood flow and temperature. The built-in thermometer can sense increases as minuscule as 0.004 degrees Celsius. Once an irregularity is detected, the sensor, which contains a micro coin cell battery for power, uses Bluetooth to alert a patient or physician via a smartphone or tablet. Any increase typically signals inflammation which is a potential sign of transplant rejection.

After any surgery that involves an organ transplant, the risk of rejection is high. The sensor was developed specifically for kidney transplants but it could also work for other organs, including the liver and lungs. Kidney transplants in the US are on the rise and are usually recommended for people who will not be able to live without dialysis. The American Kidney Fund cites that an acute rejection of a kidney transplant one month after surgery happens in about five to twenty percent of patients that go under.

That’s why it is critical to detect transplant rejection, which occurs when your body's immune system treats the new organ like a foreign object and attacks it. If a healthcare provider detects signs of rejection early enough, medical intervention can preserve the new organ in the new host. Northwestern researchers said that the device detected warning signs of organ rejection three weeks earlier than current monitoring methods. The current “gold standard” for detecting rejection is a biopsy, where a tissue sample is extracted from the transplanted organ and then analyzed in a lab. However, biopsies are invasive and can cause bleeding and increase the risk for infection.

Northwestern University

Despite developing an innovative first-of-its-kind product, researchers at Northwestern University still have a long way to go. It still needs to be tested on humans in a clinical setting before it can make any impact in the surgical market. Northwestern’s John A. Rogers, a bioelectronics expert who led the device development, said in a statement that his team is now evaluating ways to recharge the coin cell battery so that it can last a lifetime.

Victrola has introduced two new premium turntables: the Hi-Res Carbon and Hi-Res Onyx. Both products have built-in Qualcomm audio hardware that will allow for wireless vinyl record play to any Bluetooth or aptX-enabled speakers or headphones. This hardware upgrade is a major shift away from Victrola’s previous lineup which was only compatible with Sonos speakers.

The turntables support Bluetooth 5.4 and Bluetooth LE and feature Qualcomm’s aptX Adaptive audio technologies. The Hi-Res models will still feature RCA outputs for self-powered wired speakers for the more traditional crowd.

Victrola’s Hi-Res Carbon and Hi-Res Onyx models are priced at $599 and $399, respectively, and are available today. Each runs $200 cheaper than their respective Sonos-compatible counterpart.

Clearblue has launched a new product that can determine what stage of menopause a person is in. The "Menopause Stage Indicator" is a urine testing device and it's the company's first for this underserved market in women's health.

The Menopause Stage Indicator looks like a standard pregnancy test stick but instead of measuring urine for pregnancy hormones, it will look for follicle-stimulating hormone (FSH) levels, which are measured to confirm menopause. To get accurate test results, you’ll have to conduct five urine tests over ten days, and Clearblue recommends they be taken every other day. Using FSH levels, menstrual cycle history, and a person’s age, the company will be able to determine and confirm the menopause stage. The app will calculate if a person is in premenopause, early perimenopause, late perimenopause, or postmenopause.

In its press release, Clearblue acknowledges that only a healthcare professional can confirm someone’s menopause stage. However, through the app, you can generate a personalized report and share it with your healthcare provider to confirm test results and discuss potential treatment options. The Menopause Stage Indicator will be available on Amazon for a starting price of $20.

Women’s health has long been cast aside as a mere subset of healthcare. And it’s even worse for aging people entering menopause. The market for a menopause testing device by Clearblue, a brand most famous for its pregnancy tests, is prime for the taking. Studies show that 73 percent of women experience menopause but do not seek treatment for their symptoms and the global menopause market size is projected to grow to $21.6 billion by 2026.

Garmin is launching the Venu 3 and smaller Venu 3S smartwatches today with a greater focus on sleep-tracking and personalization. In particular, it's adding a proactive sleep coaching feature and nap detection. The latter is noteworthy, considering most modern smartwatches from companies like Apple, Samsung, and Google can track your sleep, but only at night. With the Venu 3 series, you'll be able to rest easy knowing your daytime slumber can also be tracked, if that's your kind of thing.  

The company's new sleep coach considers factors such as a user's daily activity levels, sleep history, and heart rate variability (HRV) – which is a sleep metric new to the Venu series. The coach will provide recommendations on the amount of sleep you’ll need to make it through the next day. The naps that the Venu 3 detects will also go towards replenishing energy levels as tracked by the company’s “Body Battery” tool, which quantifies energy levels on a scale of 1-100 depending on activity expenditure.

Aside from sleep-tracking upgrades, the Venu 3 has a host of other improvements over its predecessor. Notably, it introduces a wheelchair mode that will track pushes rather than steps, as well as handcycle activities and pre-loaded workouts for wheelchair users, offering more inclusivity. The new watch also offers expanded insights on how workouts can affect a user and how much time is needed to recover after every gym session. 

Additionally, Garmin is bringing a “rate of perceived exertion” feature, which enables users to report how challenging a workout felt. With this, the company is trying something new in the fitness arena. Instead of just crunching numbers, it’s dipping its toes into subjective data – the kind of information that's all about personal judgment and individual experiences. The Venu 3 also introduces “interval creation,” which gives a runner or biker the option to build interval workouts from the watch face.

Garmin

Beyond expanding health and fitness tracking features, Garmin says this watch will have a built-in speaker and microphone that will allow a wearer to make calls from the watch. The Venu 3 can also display photo messages on its AMOLED touchscreen. You'll be able to make contactless payments using Garmin Pay and stream music from Spotify and Amazon Music, as well.

The Venu 3 will start at $449.99 and offers up to 14 days of battery life in smartwatch mode. It features a light stainless steel bezel and has silicone bands in either white or black, while five strap color options are available for the smaller 3S.

It’s still unclear if older Venu models will receive software updates that will bring these new features over. But for a mainstream smartwatch from a company that mostly caters to a fitness-focused audience, the Venu 3 appears to be a step forward.